Manufacturing Facilities

Cosmo Pharma Ltd. is equipped with state-of-the-art manufacturing facilities designed to produce a diverse range of high-quality pharmaceutical products.

Future Expansion Plan

Local Pharmaceutical market is growing continuously due to increase of income of the people of this land and continuous improvement of this sector in terms of technology adaptation and development of management skills. At the same time a very large global market of 3.5 to 4 trillion US$ encourage us to think for the expansion of this industry to a world class pharmaceutical industry with sophisticated dosage forms including parenteral preparations, products of oncology, hormonal products, Metered Dose Inhalers(MDI) etc. After fulfillment of our mission and vision with the Cosmo Pharma, we may expand the industry for the manufacturing of medical devices which is at present dependent on import. Our dreams are focused on healthcare solutions but with the sequential steps after achieving outstanding performance in one sector then to step other sector of healthcare facilities.

New Product Launching Plan

Products in the Pipeline under registration:

Montelukast
Calcium+ Vitamin D3
Doxophylline
VitaminB_{1+ Vitamin}B₆+ Vitamin B₁₂
Amlodipine+ Losartan Potassium
Linagliptin+Metformin
Pregabalin
Losartan Potassium
Olmesartan
Olmesatan +Calcium
Pregabalin+ VitaminB_{1+ Vitamin}B₆+ Vitamin B₁₂
Sodium Alginate+ Potassium bicarbonate+ Calcium bicarbonate Suspension

Other 25 new products will be Launched by this period

Emergence on Global Pharmaceutical Market

Our Bangladesh is a densely populated country with a population of more than160 million where there are more than 282 local and multinational companies having manufacturing licenses, but practically about 207 companies exist in operation. Among these, the top 20 companies are able to gain 80% share of total market and the rest of the companies manage the other 20%. However, to both the patients as well as the registered doctors, quality medicine is the prime concern. Bangladesh exports to 147 countries 1,200 pharmaceutical products received registration for export in the last two years Beximco Pharma and Square Pharmaceuticals have received US FDA certification Beximco, Square, Incepta, ACI and Reneta, got UK MHRA (Medicines and Healthcare Products Regulatory Agency) certification.

Prospects of Bangladeshi Pharmaceutical industries in Global arena

“Bangladesh is going to be a major global hub for high quality low cost generic medicine and vaccine. India and China are losing cost advantages,” Patent waiver for the medicines and agricultural products under the guide lines of TRIPS is to be considered as a boon for Bangladesh. In 2015, the World Trade Organization (WTO) Council extended patent waivers for pharmaceuticals products for its members in the least developed countries (LDC) category to January 2033. As an LDC, Bangladesh will not need to pay royalty for producing patent drugs till 2033, which is a great opportunity for Bangladesh to improve its export share in the pharma products. In this circumstances, we, a group of doctors decided to take ownership of a pharmaceutical industry, renovate according to CGMP(Current Gooding Manufacturing Practice)-Guide line of WHO and then market the quality products. The company is Cosmo Pharma Laboratories Ltd.